Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma
NCT ID: NCT01103037
Last Updated: 2020-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
8 participants
INTERVENTIONAL
2010-03-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
QAV680
QAV680
QAV680 500 mg (5 x 100 mg capsules) four times per day
QAV680 Placebo
QAV680 Placebo
Placebo to QAV680 5 capsules four times per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QAV680
QAV680 500 mg (5 x 100 mg capsules) four times per day
QAV680 Placebo
Placebo to QAV680 5 capsules four times per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any significant disease or illness, other than asthma
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West Coast Clinical Trials
Cypress, California, United States
American Health Research
Charlotte, North Carolina, United States
North Carolina Clinical Research
Raleigh, North Carolina, United States
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Wiesbaden, , Germany
Novartis Investigative Site
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CQAV680A2201E1 from the Novartis Clinical Trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-017267-41
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CQAV680A2201E1
Identifier Type: -
Identifier Source: org_study_id